SS-31 (Elamipretide) for Plantar Fasciitis: Mitochondrial Evidence Review

What's breaking down if you have Plantar Fasciitis

Plantar fasciitis involves degenerative changes in the plantar fascia, the thick band of tissue connecting your heel bone to your toes. The tissue shows collagen disorganization, increased cell death in tenocyte-like cells, and reduced ability to handle mechanical stress from walking or standing.

If your fascia cells have mitochondrial dysfunction, energy production drops and repair slows. This creates a gap where breakdown outruns regeneration. Mitochondrial membrane potential falls, reactive oxygen species handling weakens, and genes linked to matrix breakdown rise. These layers matter because plantar fascia is under constant load; poor cellular energy makes recovery harder.

No direct human data links plantar fasciitis to SS-31. The closest evidence comes from degenerative tendon cells, which share features with fascia degeneration.

Why SS-31 (Elamipretide) might help you

1. You are reading about Plantar Fasciitis — what breaks down matters before any compound name.
2. Therefore for you: If mitochondrial dysfunction in fascia cells is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.

SS-31 concentrates in the inner mitochondrial membrane and stabilizes cardiolipin. In degenerative tenocytes from human tendon biopsies, treatment reduced the fraction of cells with depolarized mitochondria and improved mitochondrial number and size seen on electron microscopy. Superoxide dismutase activity rose after treatment. Matrix metalloproteinase-1 expression fell, and fatty acid-binding protein 4 expression dropped. Cell viability showed small improvement.

If your plantar fascia cells behave like those degenerative tenocytes, SS-31 could support mitochondrial structure and function. That might allow better ATP production for collagen maintenance and reduce signals that promote further breakdown. The study used cultured cells from patients with rotator cuff issues, not foot fascia, so direct translation remains untested.

SS-31 does not act as a pain suppressor or anti-inflammatory drug in the classic sense. It addresses cellular energy deficits that may underlie poor tissue repair in degenerative conditions.

How these fit together

Single-compound focus — SS-31 (Elamipretide) targets the mitochondrial layer. If your condition profile includes other degeneration layers such as mechanical overload or inflammation, those would require separate approaches. SS-31 addresses energy production inside cells so repair pathways have a better chance to keep pace with daily loading on the fascia.

What the evidence actually shows

The key study is an in vitro model using tenocytes from human degenerative supraspinatus tendons versus healthy hamstring tendons (Zhang et al., 2022, Am J Sports Med). Researchers cultured cells at passage 1 and exposed degenerative cells to 1 μM SS-31 for 72 hours. They measured mitochondrial depolarization, morphology via transmission electron microscopy, antioxidant enzyme activity, gene expression, and cell viability.

Findings: degenerative tenocytes had more depolarized mitochondria and smaller, fewer mitochondria. SS-31 reversed these changes. Antioxidant activity improved. Remodeling and fatty infiltration genes normalized. The study is preclinical (human cells in culture) and does not prove effects in living people with plantar fasciitis.

Human trials of SS-31 exist for primary mitochondrial myopathy and Barth syndrome. One phase 2/3 trial in Barth syndrome showed functional improvements in the open-label extension but missed primary endpoints in the blinded phase. No trials test SS-31 in plantar fasciitis or any foot condition.

What scientists say

The tendinopathy paper concludes that mitochondrial dysfunction appears in degenerative tenocytes and SS-31 may improve mitochondrial function to promote healing. Authors note clinical relevance for tendinopathy but call for further work. Broader reviews describe SS-31 as a cardiolipin stabilizer that supports electron transport and reduces oxidative stress in multiple mitochondrial disease models. No published statements address plantar fasciitis specifically.

What people say on Reddit

No posts or threads were identified discussing SS-31 or elamipretide in the context of plantar fasciitis or foot pain. Searches returned zero relevant anecdotes.

What people say on X

No posts were identified linking SS-31 to plantar fasciitis. General discussions of the peptide focus on Barth syndrome approval or mitochondrial myopathy trials.

What we do not know

No human trials exist for SS-31 in plantar fasciitis. No animal models of plantar fasciitis treated with SS-31 have been published. Whether improved mitochondrial function in cultured tendon cells translates to fascia repair in vivo remains unknown. Long-term safety and functional outcomes in musculoskeletal tissues are unstudied for this indication. Weight loss can reduce compressive forces on the plantar fascia (roughly 4 lb per pound lost), but SS-31 itself has no documented effect on body weight.

Safety and limits

SS-31 has been tested in human trials for mitochondrial myopathy and Barth syndrome with generally good tolerability reported. Common side effects in those studies were mild and included injection-site reactions. The compound received FDA approval for Barth syndrome in 2025. All other uses remain investigational. No data exist on interactions with common plantar fasciitis treatments or on long-term use in otherwise healthy individuals. This review reports published findings only and does not constitute guidance.